HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)

Market Cap	6.07B +10.2%
Revenue (ttm)	2.12B -11.5%
Net Income	411.58M +71.0%
EPS	0.18 +74.4%
Shares Out	2.23B
PE Ratio	14.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,708,515
Open	2.860
Previous Close	2.710
Day's Range	2.660 - 2.860
52-Week Range	2.670 - 4.080
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 24, 2026

About SHE:002437

HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People’s Republic of China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 2,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002437

Financial Performance

In 2025, SHE:002437's revenue was 2.14 billion, a decrease of -12.51% compared to the previous year's 2.44 billion. Earnings were 376.91 million, an increase of 61.93%.